Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ABI-110 by Avirmax for Polypoidal Choroidal Vasculopathy: Likelihood of Approval
ABI-110 is under clinical development by Avirmax and currently in Phase II for Polypoidal Choroidal Vasculopathy. According to GlobalData, Phase...
Data Insights
ABI-110 by Avirmax for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
ABI-110 is under clinical development by Avirmax and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According...